+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function

Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function

Journal of Pediatric Endocrinology & Metabolism 13(2): 179-184

Objective: Iron deposition in the anterior pituitary continues to pose a serious problem in older patients with homozygous beta-thalassemia - particularly in terms of gonadal function. This study aimed to investigate whether iron loading within the pituitary correlated with endocrine function. Patients: 33 patients above 15 years of age, with transfusion-dependent homozygous beta-thalassemia and iron overload were studied. All had been receiving deferoxamine since 1978. Design and Measurements: The endocrine status of the patients was assessed on clinical examination by an endocrinologist, and by a gonadotropin releasing hormone stimulation test. MRI of the pituitary was carried out for each patient. Results: Anterior pituitary function (GnRH stimulation test) correlated well with MRI results. However, no correlation was found between the MRI measurements, the GnRH stimulation test and the clinical status of the patients, as 28 out of the 33 patients achieved normal puberty. Conclusions: MRI in conjunction with a GnRH stimulation test may be useful in predicting future impairment of pituitary function; however, further studies are needed to assess the effect of chelation therapy on the iron overload in the gland.

(PDF emailed within 0-6 h: $19.90)

Accession: 010885187

Download citation: RISBibTeXText

PMID: 10711663

DOI: 10.1515/JPEM.2000.13.2.179

Related references

Differential iron deposition in the anterior pituitary and liver in homozygous beta-thalassemia Prediction of gonadal failure by magnetic resonance imaging. Blood 82(10 SUPPL 1): 359A, 1993

MRI of the liver and the pituitary gland in patients with beta-thalassemia major: does hepatic siderosis predict pituitary iron deposition?. European Radiology 13(1): 12-16, 2003

One-stop measurement of iron deposition in the anterior pituitary, liver, and heart in thalassemia patients. Journal of Magnetic Resonance Imaging 28(1): 29-33, 2008

Correlation between pharmacokinetics and iron excretion pharmacodynamics of 1,2-dimethyl-3-hydroxypyrid-4-one , in homozygous beta-thalassemia patients. Clinical & Investigative Medicine 16(4 SUPPL ): B22, 1993

Hypothalamic-pituitary-gonadal function in adolescent females with beta-thalassemia major. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 90(1): 44-47, 2005

Relationship of myocardial iron overload to right and left ventricular function in homozygous beta-thalassemia. Blood 96(11 Part 1): 605a, November 16, 2000

Evaluation of auditory function in homozygous beta-thalassemia. La Pediatria Medica E Chirurgica 8(5): 703-705, 1986

Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. New England Journal of Medicine 323(11): 713-719, 1990

Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously. La Pediatria 91(4): 371-377, 1983

Evaluation of semen quality, endocrine profile and hypothalamus-pituitary-testis axis in male patients with homozygous beta-thalassemia major. Journal of Urology 179(6): 2327-2332, 2008

A noninvasive method for the evaluation of tissue iron deposition in beta-thalassemia major. Journal of Laboratory and Clinical Medicine 91(1): 24-31, 1978

Pituitary somatotropic and corticotropic function in patients with beta-thalassemia on iron chelation therapy. Birth Defects Original Article Series 23(5a): 449-452, 1987

Effective iron chelation using the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one , in homozygous beta-thalassemia major patients. Clinical Pharmacology & Therapeutics 53(2): 145, 1993

Beta-thalassemia major: thin-section CT features and correlation with pulmonary function and iron overload. Radiology 229(2): 507-512, 2003

Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia. Clinical Pharmacology and Therapeutics 55(1): 70-75, 1994